Thanks for the answers re ph1 vs ph2 for new diseases.Very...

Thanks for the answers re ph1 vs ph2 for new diseases.
Very interesting/ballsy MT meeting with Amylx directors, given that they are effectively wounded competitors. Would be interesting to know his intentions here?
Amylx have knowledge, distribution capability, relationships, cash- all they are lacking is leverage of any kind, so perhaps a much better deal can be struck with them than BP?
Amylx are completely screwed.
Do they slowly fritter away their capital trying to flog a dead horse? No
Do they liquidate at fire sale prices to salvage cents in the dollar? Maybe in worst case scenario.
Do they acquire a strategic asset and reinvent themselves? Perhaps, but not many targets in MND space worth buying. I doubt they could afford a clean buyout of PAA (surely a better funded BP would out-bid them?)
Otherwise they buy an unrelated asset- not much synergy, loss of specific MND related IP and skillsets.
These are all pretty crappy options.
So now imagine a reverse T/O where PAA actually buys the pharma as a means to IPO!! Scoop up the dead corpse (Amylx) and retain the staff and infrastructure... their cash holdings would be a problem, but not insurmountable- either force them to declare a dividend pre-T/O or just cook a bigger pie.
This solves the problem of selling MND and losing PD, Alzheimers, cancer, etc along with it (ie. We would then be a beast with greater resources to develop these either alone or with a partner)
It is astronomical to think of, but we would be picking up a very vulnerable asset and could absolutely run with it.
This would maximise Amylx shareholder return too.
If this is what MT/Roger are up to and they pull it off there will be textbooks written about it.